Literature DB >> 30187947

MiR-134-5p attenuates neuropathic pain progression through targeting Twist1.

Li-Juan Ji1, Jing Su2, An-Le Xu1, Bo Pang1, Qiang-Min Huang1.   

Abstract

Neuropathic pain is a kind of chronic pain because of dysfunctions of somatosensory nerve system. Recently, many studies have demonstrated that microRNAs (miRs) play crucial roles in neuropathic pain development. This study was designed to investigate the effects of miR-134-5p on the process of neuropathic pain progression in a rat model established by chronic sciatic nerve injury (CCI). First, we observed that miR-134-5p was significantly decreased in CCI rat models. Overexpression of miR-134-5p strongly alleviated neuropathic pain behaviors including mechanical and thermal hyperalgesia. Meanwhile, inflammatory cytokine expression, such as IL-6, IL-1β and TNF-α in CCI rats were greatly repressed by upregulation of miR-134-5p. Twist1 has been widely regarded as a poor prognosis biomarker in diverse diseases. Here, by using bioinformatic analysis, 3'-untranslated region (UTR) of Twist1 was predicted to be a downstream target of miR-134-5p in our study. Here, we found that overexpression of miR-134-5p was able to suppress Twist1 dramatically. Furthermore, it was exhibited that Twist1 was increased in CCI rats time-dependently and Twist1 was inhibited in vivo. Subsequently, downregulation of Twist1 in CCI rats could depress neuropathic pain progression via inhibiting neuroinflammation. In conclusion, our current study indicated that miR-134-5p may inhibit neuropathic pain development through targeting Twist1. Our findings suggested that miR-134-5p might provide a novel therapeutic target for neuropathic pain.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Twist1; inflammation; miR-134-5p; neuropathic pain

Year:  2018        PMID: 30187947     DOI: 10.1002/jcb.27486

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  3 in total

Review 1.  New Vistas in microRNA Regulatory Interactome in Neuropathic Pain.

Authors:  Yash Gada; Amitkumar Pandey; Nikita Jadhav; Saiprasad Ajgaonkar; Dilip Mehta; Sujit Nair
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

2.  METTL3 suppresses neuropathic pain via modulating N6-methyladenosine-dependent primary miR-150 processing.

Authors:  Le Zhang; Xin Zhao; Jing Wang; Yanwu Jin; Moxuan Gong; Yuyang Ye; Peilong Li
Journal:  Cell Death Discov       Date:  2022-02-24

3.  Homoharringtonine Inhibits Allergic Inflammations by Regulating NF-κB-miR-183-5p-BTG1 Axis.

Authors:  Misun Kim; Hyein Jo; Yoojung Kwon; Youngmi Kim; Hyun Suk Jung; Dooil Jeoung
Journal:  Front Pharmacol       Date:  2020-07-07       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.